TYK Medicines, Inc (HKG:2410)
Hong Kong
· Delayed Price · Currency is HKD
9.97
-0.15 (-1.48%)
Apr 29, 2026, 4:08 PM HKT
TYK Medicines Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Revenue | - | 0.11 | - | 44.24 |
| Cost of Revenue | - | 0.09 | - | 24.2 |
| Gross Profit | - | 0.01 | - | 20.04 |
| Selling, General & Admin | 78.48 | 108.33 | 59.31 | 33.54 |
| Research & Development | 244.06 | 235.45 | 249.25 | 229.81 |
| Operating Expenses | 322.54 | 343.78 | 308.56 | 263.35 |
| Operating Income | -322.54 | -343.76 | -308.56 | -243.31 |
| Interest Expense | -14.92 | -12.57 | -8.73 | -3.26 |
| Interest & Investment Income | 2.74 | 3.28 | 3.73 | 7.37 |
| Currency Exchange Gain (Loss) | 5.12 | 0.29 | 0.1 | - |
| Other Non Operating Income (Expenses) | 20.92 | -35.21 | -68.98 | -72.87 |
| EBT Excluding Unusual Items | -308.69 | -387.97 | -382.44 | -312.06 |
| Gain (Loss) on Sale of Investments | - | -0 | -0.73 | 0.34 |
| Gain (Loss) on Sale of Assets | - | 0.04 | -0.01 | -0.04 |
| Other Unusual Items | 2.71 | 0 | 0.01 | -0.05 |
| Pretax Income | -305.97 | -387.93 | -383.17 | -311.8 |
| Earnings From Continuing Operations | -305.97 | -387.93 | -383.17 | -311.8 |
| Minority Interest in Earnings | 6.2 | 0.97 | 0.74 | 0.81 |
| Net Income | -299.77 | -386.96 | -382.43 | -310.99 |
| Net Income to Common | -299.77 | -386.96 | -382.43 | -310.99 |
| Shares Outstanding (Basic) | 375 | 338 | 289 | 278 |
| Shares Outstanding (Diluted) | 375 | 338 | 289 | 278 |
| Shares Change (YoY) | 10.94% | 16.91% | 3.94% | - |
| EPS (Basic) | -0.80 | -1.15 | -1.32 | -1.12 |
| EPS (Diluted) | -0.80 | -1.15 | -1.32 | -1.12 |
| Free Cash Flow | - | -381.87 | -277.32 | -279.02 |
| Free Cash Flow Per Share | - | -1.13 | -0.96 | -1.00 |
| Gross Margin | - | 13.08% | - | 45.30% |
| Operating Margin | - | -321274.77% | - | -549.94% |
| Profit Margin | - | -361640.19% | - | -702.94% |
| Free Cash Flow Margin | - | -356891.59% | - | -630.67% |
| EBITDA | -307.61 | -328.83 | -295.1 | -232.31 |
| D&A For EBITDA | 14.93 | 14.93 | 13.46 | 11 |
| EBIT | -322.54 | -343.76 | -308.56 | -243.31 |
Source: S&P Capital IQ. Standard template.
Financial Sources.